Recently, a series of pipeline 온라인 바카라s, including CAR-T and NK cell technologies, have been sequentially registered
[by Ji, Yong Jun] Vaxcellbio revealed on April 23 that it has officially registered a Japanese patent for its core immune cell therapy technology named ‘Composition for proliferation of natural killer cells containing feeder cells.’
The patented technology represents an advanced platform developed by 온라인 바카라 that utilizes ‘feeder cells’ to proliferate NK cells. These feeder cells are engineered to express specific genes that facilitate the production of high-purity and enhanced cytotoxicity. Compared to conventional feeder cell-based methods, this technology significantly improves the efficiency of NK cell production, achieving higher expansion rates and purity.
온라인 바카라 stated that the patent was filed simultaneously in eight countries, including Korea, with Europe considered as a single region. Among these, Japan was the first to grant registration approval, a development the company views as particularly meaningful. Japan is recognized for its rigorous and advanced patent examination standards in the life sciences and biotechnology sectors, often imposing especially stringent requirements for technological sophistication and clarity of composition, particularly on foreign biotechnology companies.
This Japanese patent marks the third core technology patent that 온라인 바카라 has secured in Korea and internationally this year. This month alone, the company has registered two additional patents: one for a ‘monobody-based chimeric antigen receptor’ and another for a ‘novel manufacturing method of natural killer cells and a liver cancer treatment method using the same,’ both of which are related to its CAR-T development pipeline. These recent additions significantly bolster 온라인 바카라 Bio’s intellectual property (IP) portfolio, which now spans multiple therapeutic pipelines.
온라인 바카라 now holds a total of 14 domestic and international patents, encompassing advanced technologies related to NK cells, CARs, feeder cells, and canine interleukin-15. In addition, the company currently has six new patent applications pending, including those for bone marrow-infiltrating lymphocytes and dual-target CAR-T treatments.
“We intend to leverage the registration of this Japanese patent as a strategic foothold to progressively expand the international scope of our patent portfolio across various technologies. This will serve as a foundation for strengthening technology-driven partnerships and commercialization efforts, not only with Korean firms but also with global pharmaceutical and biotechnology companies,” said Lee Je-jung, CEO of 온라인 바카라. “Our company is actively engaged in international joint research in the immunotherapy field, including CAR-NK, and we are concurrently exploring opportunities in contract development and manufacturing organization (CDMO) services, supported by advanced regenerative medicine GMP facilities that have received government approval.”